SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!!
IGT 16.66+0.4%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BobBeaty who wrote (43)12/29/1998 10:56:00 AM
From: Spiney  Read Replies (1) of 86
 
IGT Pharma receives authorization to start human trial

IGT Pharma Inc IGT
Shares issued 8,819,820 Dec 24 close $0.77
Tue 29 Dec 98 News Release
Mr. Bruce Schmidt reports
IGT has received authorization from the Therapeutic Products Program of
Health Canada to start a phase 1 human clinical trial using the new cancer
drug, Anhydrovinblastine. The approval, received in the form of a letter of
no objection, allows for the immediate staging of all aspects of the study.
The purpose of a phase 1 clinical trial is to determine the safety and dose
ranging factors that will lead to the optimum dose level for treating
patients in subsequent studies. Whereas the phase 1 study will involve a
maximum of 30 patients who may have various forms of cancer, further
studies will involve only patients with non-small call lung cancer. Lung
cancer is the most common form of cancer in the United States, with over 75
per cent of those cases being the non-small cell type.
The commencement of human clinical trials is a significant milestone for
companies such as IGT as it is typically when major pharmaceutical
companies develop an active interest in new cancer products. Partnership
with these multi-national companies would provide IGT with return on
investment through licencing fees, marketing rights and involvement in
latter stage clinical trials.
In addition to AVLB, the company has recently started the development of
its second cancer drug targeted at drug resistant cancers. Areas of
neurological drug development include the treatment of schizophrenia,
anxiety, stroke and epilepsy.
(c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com

-------------------------

don't know why they announced this...?


the company says they are waiting for FDA approval which should come any day now.

my apologies if this prints a few times - I'm having problems connecting to SI this morning.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News